Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.


BWXT Commercial Operations Names Monifa Miller as Senior Director of Corporate Affairs

13 February 2023

(CAMBRIDGE, ON – February 13, 2023) – BWX Technologies, Inc. (NYSE: BWXT) has appointed Monifa A. Miller as senior director of corporate affairs for BWXT’s Commercial Operations segment. In this role, she will have full responsibility for all of BWXT’s communications, public affairs, government relations and community outreach activities in Canada.

BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone

01 February 2023

(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks to the installation and initial commissioning of an innovative isotope system by Laurentis Energy Partners and BWXT Medical Ltd. (NYSE: BWXT).

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

05 January 2023

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.

BWXT Promotes Chip Whitford to Senior Vice President and General Counsel

04 January 2023

BWX Technologies, Inc. (NYSE: BWXT) has promoted Ronald O. (Chip) Whitford, Jr. to the position of senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 2, 2023.

BWXT Names Omar Meguid Chief Digital Officer

03 January 2023

BWX Technologies, Inc. (NYSE: BWXT) has named Omar Meguid as senior vice president and chief digital officer effective January 1, 2023.

BWXT Starts Production of TRISO Fuel for First U.S. Generation IV Microreactor

07 December 2022

BWX Technologies, Inc. (NYSE: BWXT) today with officials from the U.S. Department of Defense, Department of Energy, NASA and Idaho National Laboratory celebrated the landmark production of TRISO nuclear fuel that will power the first microreactor built and operated in the United States.

BWX Technologies Reports Third Quarter 2022 Results

07 November 2022

LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported third quarter 2022 GAAP net income attributable to BWXT of $61.6 million, or diluted earnings per share (EPS) of $0.67, on revenue of $523.7 million. Third quarter 2022 non-GAAP(1) net income attributable to BWXT was $63.0 million, or $0.69 diluted EPS. Third quarter 2022 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA)(1) was $100.1 million. A reconciliation of non-GAAP results are detailed in Exhibit 1.

BWXT Closes Amended and Restated Credit Agreement

12 October 2022

(LYNCHBURG, Va. – Oct. 12, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that it has closed on an amended and restated credit agreement with Wells Fargo Bank, N.A. and other lenders that increases the company’s liquidity while improving a number of key terms for BWXT.

BWX Technologies to Announce Third Quarter 2022 Results on Monday, November 7

12 October 2022

LYNCHBURG, Va.--(BUSINESS WIRE)-- BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing third quarter 2022 results on Monday, November 7, 2022, after market close and will host a conference call at 5:00 p.m. EST.

BWXT Medical Submits Tc-99m Generator New Drug Application to FDA

13 September 2022

Company Highlights Growing Nuclear Medicine Product Portfolio and Future Opportunities in Therapeutic Radioisotopes

Press Contacts:

BWX Technologies, Inc.

Jud Simmons 
+1 434.522.3800

BWXT Canada Ltd.
BWXT Nuclear Energy Canada Inc.
BWXT Medical Ltd.

Monifa Miller
+1 519.242.8071

Nuclear Fuel Services, Inc.

Laura Bailey 
+1 423.743.9141